Navigating Newer Treatment Regimens in Melanoma: Practical Approaches to Dosing and Adverse Event Management
Panelists discuss how community oncologists have developed good experience managing immune-related adverse events and are increasingly adopting relatlimab-nivolumab due to its lower toxicity profile and convenient administration schedule of half-hour infusions every four weeks.
Adoption of Newer Immunotherapy Regimens
Key Discussion Points:
- Community adoption of newer immunotherapy combinations
- Evidence-based decision-making in regimen selection
- Factors influencing uptake of nivolumab/relatlimab in clinical practice
Key Points for Physicians:
- Long-term efficacy data from CheckMate 067 continues to influence treatment selection, though growing confidence in nivolumab/relatlimab is emerging with longer follow-up
- Practical advantages of nivolumab/relatlimab include its 30-minute infusion every 4 weeks schedule and improved toxicity profile
- Pathways and prescribing protocols generally allow flexibility in selecting between available immunotherapy regimens
Notable Insights:
Community oncologists typically prioritize evidence-based decision-making, with increasing comfort using nivolumab/relatlimab as longer-term efficacy data becomes available, including the recent 4-year follow-up and indirect treatment comparison data.
Clinical Significance:
Adoption of newer immunotherapy combinations is primarily driven by accumulating efficacy data and real-world experience, with treatment selection ultimately guided by individual patient factors and physician experience with managing toxicities.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
